{"prompt": "['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', '12.3.', 'Appendix 3: Contraceptive Guidance and Collection of', 'Pregnancy Information', 'Definitions', 'Woman of Childbearing Potential (WOCBP)', 'A woman is considered fertile following menarche and until becoming post-menopausal', 'unless permanently sterile (see below)', 'Women in the following categories are not considered WOCBP', '1. Premenarchal', '2. Premenopausal female with ONE of the following:', 'Documented hysterectomy', 'Documented bilateral salpingectomy', 'Documented bilateral oophorectomy', \"Note: Documentation can come from the site personnel's: review of Participants's\", 'medical records, medical examination, or medical history interview.', '3. Postmenopausal female', 'A postmenopausal state is defined as no menses for 12 months without an', 'alternative medical cause. A high follicle stimulating hormone (FSH) level in', 'the postmenopausal range may be used to confirm a postmenopausal state in', 'women not using hormonal contraception or hormonal replacement therapy', '(HRT). However, in the absence of 12 months of amenorrhea, a single FSH', 'measurement is insufficient.', 'Females on HRT and whose menopausal status is in doubt will be required to', 'use one of the non-hormonal highly effective contraception methods if they wish', 'to continue their HRT during the study. Otherwise, they must discontinue HRT', 'to allow confirmation of postmenopausal status before study enrollment.', 'Contraception Guidance', 'Female Participants', 'Female participants of childbearing potential are eligible to participate if they agree to', 'use a highly effective method of contraception consistently and correctly as described in', 'Table 5.', '85']['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', 'Table 5', 'Highly Effective Contraceptive Methods', 'Highly Effective Contraceptive Methods That Are User Dependent a', 'Failure rate of <1 % per year when used consistently and correctly.', 'Combined (estrogen- and progestogen-containing) hormonal contraception associated with', 'inhibition of ovulationb', 'oral', 'intravaginal', 'transdermal', 'Progestogen-only hormonal contraception associated with inhibition of ovulation', 'injectable', 'Highly Effective Methods That Are User Independent', 'Implantable progestogen-only hormonal contraception associated with inhibition of', 'ovulationb', 'Intrauterine device (IUD)', 'Intrauterine hormone-releasing system (IUS)', 'bilateral tubal occlusion', 'Vasectomized partner', '(A vasectomized partner is a highly effective contraception method provided that the partner is', 'the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If', 'not, an additional highly effective method of contraception should be used.)', 'Sexual abstinence', '(Sexual abstinence is considered a highly effective method only if defined as refraining from', 'heterosexual intercourse during the entire period of risk associated with the study drug. The', 'reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and', 'the preferred and usual lifestyle of the Participants.)', 'NOTES:', 'a.', 'Typical use failure rates may differ from those when used consistently and correctly. Use should be consistent', 'with local regulations regarding the use of contraceptive methods for Participantss in clinical studies.', 'b.', 'Hormonal contraception may be susceptible to interaction with the study drug, which may reduce the efficacy of', 'the contraceptive method. In this case two highly effective methods of contraception should be utilized during the', 'treatment period.', 'Pregnancy Testing', 'WOCBP should only be included after a confirmed menstrual period and a negative', 'highly sensitive urine pregnancy test', '86']['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', 'Additional pregnancy testing should be performed during the treatment period (see', 'SoA) and whenever a menstrual cycle is missed or when pregnancy is otherwise', 'suspected', 'Pregnancy testing will be performed using the test kit provided by the central', 'laboratory and in accordance with instructions provided in its package insert', 'Collection of Pregnancy Information', 'Female participants who become pregnant', 'Investigator will collect pregnancy information on any female participant, who', 'becomes pregnant while participating in this study.', 'Information will be recorded on the appropriate form and submitted to GSK within', \"24 hours of learning of a participant's pregnancy.\", 'Participants will be followed to determine the outcome of the pregnancy. The', 'Investigator will collect follow up information on participant and neonate, which will', 'be forwarded to GSK. Generally, follow-up will not be required for longer than 6 to', '8 weeks beyond the estimated delivery date.', 'Any termination of pregnancy will be reported, regardless of fetal status (presence or', 'absence of anomalies) or indication for procedure.', 'While pregnancy itself is not considered to be an AE or SAE, any pregnancy', 'complication or elective termination of a pregnancy will be reported as an AE or', 'SAE.', 'A spontaneous abortion is always considered to be an SAE and will be reported as', 'such.', 'Any SAE occurring as a result of a post-study pregnancy which is considered', 'reasonably related to the study treatment by the Investigator, will be reported to GSK', 'as described in Appendix 6. While the Investigator is not obligated to actively seek', 'this information in former study participants, he or she may learn of an SAE through', 'spontaneous reporting.', 'Any female participant who becomes pregnant while participating in the study', 'will immediately discontinue study medication.', '87']\n\n###\n\n", "completion": "END"}